Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Jean-Pierre Bizzari, insider at Halozyme Therapeutics
Jean-Pierre Bizzari Insider Alerts

Get notified the next time Jean-Pierre Bizzari buys or sells Halozyme Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Jean-Pierre Bizzari Insider Information

Dr. Bizzari brings extensive experience in oncology drug development. He was Executive Vice President and Global Head of Oncology at Celgene Corporation, responsible for Celgene’s clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan where he oversaw the development and approval of a number of leading oncology products, including REVLIMID® (lenalidomide), VIDAZA®(azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). In addition, he was Chairman of Celgene’s hematology oncology development committee and a member of the company’s management committee. Prior to Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute and a member of the board of directors of Compugen Ltd., Nordic Nanovector ASA, Onxeo SA, and Transgene SA. He is a Doctor of Medicine, a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Dr. Bizzari serves on the Nominating and Corporate Governance Committee.

How do I contact Jean-Pierre Bizzari?

The corporate mailing address for Mr. Bizzari and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]

Has Jean-Pierre Bizzari been buying or selling shares of Halozyme Therapeutics?

Jean-Pierre Bizzari has not been actively trading shares of Halozyme Therapeutics over the course of the past ninety days. Most recently, Jean-Pierre Bizzari sold 35,000 shares of the business's stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $41.01, for a transaction totalling $1,435,350.00.

Who are Halozyme Therapeutics' active insiders?

Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Connie Matsui (Director), and Helen Torley (CEO).

Are insiders buying or selling shares of Halozyme Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 750,864 shares worth more than $32,094,106.28. The most recent insider tranaction occured on November, 8th when CEO Helen Torley sold 50,000 shares worth more than $1,991,000.00. Insiders at Halozyme Therapeutics own 2.6 % of the company.

Information on this page was last updated on 11/8/2021.

Jean-Pierre Bizzari Insider Trading History at Halozyme Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2021Sell35,000$41.01$1,435,350.00View SEC Filing Icon  
See Full Table

Jean-Pierre Bizzari Buying and Selling Activity at Halozyme Therapeutics

This chart shows Jean-Pierre Bizzari's buying and selling at Halozyme Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Halozyme Therapeutics Company Overview

Halozyme Therapeutics logo
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $32.40
Low: $31.79
High: $33.38

50 Day Range

MA: $37.63
Low: $32.17
High: $40.75

2 Week Range

Now: $32.40
Low: $31.79
High: $56.40

Volume

907,856 shs

Average Volume

765,519 shs

Market Capitalization

$4.56 billion

P/E Ratio

11.61

Dividend Yield

N/A

Beta

1.25
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!